Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma
Chiung-Chi Cheng, Wei‐Ting Chao, Jing-Hao Shih, Yih-Shyong Lai, Yung-Hsiang Hsu, Yi-Hsiang Liu
Topics & Concepts
SorafenibDasatinibAngiogenesisCancer researchProto-oncogene tyrosine-protein kinase SrcVascular endothelial growth factorViability assayEndothelial stem cellHuman umbilical vein endothelial cellCell growthCellMedicineChemistryBiologyKinaseHepatocellular carcinomaCell biologyBiochemistryImatinibVEGF receptorsMyeloid leukemiaIn vitroHepatocellular Carcinoma Treatment and PrognosisAngiogenesis and VEGF in CancerLiver physiology and pathology